Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients
Abstract Background Chemokines (chemotactic cytokines) are small proteins which are engaged in many pathophysiological processes, including inflammation and homeostasis. In recent years, application of chemokines in transplant medicine was intensively studied. The aim of this study was to determine...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.901 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849730798561787904 |
|---|---|
| author | Michal Gniewkiewicz Jolanta Gozdowska Dominika Deborska‐Materkowska Katarzyna Czerwinska Agnieszka Perkowska‐Ptasinska Anna Burban Aleksandra Cieslik Maciej Kosieradzki Magdalena Durlik |
| author_facet | Michal Gniewkiewicz Jolanta Gozdowska Dominika Deborska‐Materkowska Katarzyna Czerwinska Agnieszka Perkowska‐Ptasinska Anna Burban Aleksandra Cieslik Maciej Kosieradzki Magdalena Durlik |
| author_sort | Michal Gniewkiewicz |
| collection | DOAJ |
| description | Abstract Background Chemokines (chemotactic cytokines) are small proteins which are engaged in many pathophysiological processes, including inflammation and homeostasis. In recent years, application of chemokines in transplant medicine was intensively studied. The aim of this study was to determine the utility of urinary chemokines CCL2 (C‐C motif ligand 2) and CXCL10 (C‐X‐C motif chemokine ligand 10) in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in renal transplant recipients. Methods Forty patients who had a protocol biopsy 1 year after renal transplantation were included. Concentrations of CCL2 and CXCL10 in urine with reference to urine creatinine were measured. All patients were under the supervision of one transplant center. Long‐term outcomes within 5 years after 1‐year posttransplant biopsy were analyzed. Results Urinary CCL2:Cr at the time of biopsy was significantly increased in patients who died or had graft failure. CCL2:Cr was proven to be a significant predictor of 5‐year graft failure and mortality (odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.02–1.19, p = .02; OR: 1.08, 95% CI: 1.02–1.16, p = .04; respectively). Conclusion Chemokines are easily detected by current methods. In the era of personalized medicine, urinary CCL2:Cr can be considered as a factor providing complementary information regarding risk of graft failure or increased mortality. |
| format | Article |
| id | doaj-art-98f279e37c1243f2b3206fed1ad9e4e8 |
| institution | DOAJ |
| issn | 2050-4527 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-98f279e37c1243f2b3206fed1ad9e4e82025-08-20T03:08:46ZengWileyImmunity, Inflammation and Disease2050-45272023-06-01116n/an/a10.1002/iid3.901Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipientsMichal Gniewkiewicz0Jolanta Gozdowska1Dominika Deborska‐Materkowska2Katarzyna Czerwinska3Agnieszka Perkowska‐Ptasinska4Anna Burban5Aleksandra Cieslik6Maciej Kosieradzki7Magdalena Durlik8Department of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of Pathology Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandDepartment of General and Transplantation Surgery Medical University of Warsaw Warsaw PolandDepartment of Transplantation Medicine, Nephrology and Internal Medicine Medical University of Warsaw Warsaw PolandAbstract Background Chemokines (chemotactic cytokines) are small proteins which are engaged in many pathophysiological processes, including inflammation and homeostasis. In recent years, application of chemokines in transplant medicine was intensively studied. The aim of this study was to determine the utility of urinary chemokines CCL2 (C‐C motif ligand 2) and CXCL10 (C‐X‐C motif chemokine ligand 10) in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in renal transplant recipients. Methods Forty patients who had a protocol biopsy 1 year after renal transplantation were included. Concentrations of CCL2 and CXCL10 in urine with reference to urine creatinine were measured. All patients were under the supervision of one transplant center. Long‐term outcomes within 5 years after 1‐year posttransplant biopsy were analyzed. Results Urinary CCL2:Cr at the time of biopsy was significantly increased in patients who died or had graft failure. CCL2:Cr was proven to be a significant predictor of 5‐year graft failure and mortality (odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.02–1.19, p = .02; OR: 1.08, 95% CI: 1.02–1.16, p = .04; respectively). Conclusion Chemokines are easily detected by current methods. In the era of personalized medicine, urinary CCL2:Cr can be considered as a factor providing complementary information regarding risk of graft failure or increased mortality.https://doi.org/10.1002/iid3.901CCL2chemokineskidney transplant |
| spellingShingle | Michal Gniewkiewicz Jolanta Gozdowska Dominika Deborska‐Materkowska Katarzyna Czerwinska Agnieszka Perkowska‐Ptasinska Anna Burban Aleksandra Cieslik Maciej Kosieradzki Magdalena Durlik Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients Immunity, Inflammation and Disease CCL2 chemokines kidney transplant |
| title | Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients |
| title_full | Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients |
| title_fullStr | Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients |
| title_full_unstemmed | Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients |
| title_short | Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5‐year graft failure and mortality post 1‐year protocol biopsy in kidney transplant recipients |
| title_sort | potential utility of urinary chemokine ccl2 to creatinine ratio in prognosis of 5 year graft failure and mortality post 1 year protocol biopsy in kidney transplant recipients |
| topic | CCL2 chemokines kidney transplant |
| url | https://doi.org/10.1002/iid3.901 |
| work_keys_str_mv | AT michalgniewkiewicz potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT jolantagozdowska potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT dominikadeborskamaterkowska potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT katarzynaczerwinska potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT agnieszkaperkowskaptasinska potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT annaburban potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT aleksandracieslik potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT maciejkosieradzki potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients AT magdalenadurlik potentialutilityofurinarychemokineccl2tocreatinineratioinprognosisof5yeargraftfailureandmortalitypost1yearprotocolbiopsyinkidneytransplantrecipients |